Canada Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5750-0.0244 (-4.07%)
At close: 04:00PM EDT
0.6100 +0.04 (+6.09%)
After hours: 07:55PM EDT

Brooklyn ImmunoTherapeutics, Inc.

10355 Science Center Drive
Suite 150
San Diego, CA 92121
United States
212 582 1199

Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Howard J. Federoff M.D., Ph.D.CEO, Pres & Director608.81kN/A1954
Dr. Kevin A. D'Amour Ph.D.Chief Scientific Officer448.62kN/A1973
Dr. Roger Sidhu M.D.Chief Medical Officer501.95kN/A1976
Ms. Sandra M. GurrolaVP of Fin.N/AN/A1967
Dr. Monil Shah M.B.A., Pharm.D.Chief Operating OfficerN/AN/AN/A
Mr. Jay SialChief Admin. OfficerN/AN/A1965
Ms. Lynn Sadowski Mason M.S.Exec. VP of Clinical OperationsN/AN/A1979
Ms. Susan McClatcheyVP & Head of QualityN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Corporate Governance

Brooklyn ImmunoTherapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.